Clinical trial
Interleukin-12 in Treating Patients With Advanced Cancer
NCT00003330 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003330 |
|---|---|
| Title | Interleukin-12 in Treating Patients With Advanced Cancer |
| Official title | Phase I Clinical Trials of IV rhIL-12 With or Without a Test-Dose in Patients With Advanced Malignancies (rhIL-12 NSC# 672423) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | recombinant interleukin-12 |
| Enrollment | 54 |
| Start date | Jul 1, 1998 |
| Primary completion | Apr 1, 2002 |
| First posted | May 20, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: